The Ipsen Investment Case

Oncology Key ongoing clinical-trial highlights Trial Population Patients Design Cabometyx COSMIC-312 1L HCC 740 Phase III NCT03755791 Cabometyx COSMIC-311 Phase III NCT03690388 Cabometyx CONTACT-01 Phase III NCT04471428 Sorafenib or Cabometyx + atezolizumab or Cabometyx Endpoints Primary: PFS, OS Secondary: PFS single- agent Cabometyx arm Placebo 2L RR DTC 300 or Primary: PFS, ORR Cabometyx Docetaxel or 2L NSCLC 350 Cabometyx + atezolizumab Primary: OS Secondary: PFS, ORR, DoR Status PFS primary endpoint met. Interim OS primary endpoint not met Final OS data readout expected H1 2022 PFS primary endpoint met. ORR primary endpoint not met EU regulatory decision anticipated H1 2022 Data readout anticipated H2 2022 IPSEN Innovation for patient care PFS: progression-free survival; OS: overall survival; ORR: objective response rate; DoR: duration of response. 27

View entire presentation